RUT 58 60

Drug Profile

RUT 58 60

Alternative Names: RUT58-60

Latest Information Update: 11 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oculus Innovative Sciences
  • Developer Pulmatrix
  • Class Antibacterials
  • Mechanism of Action Angiogenesis inducing agents; Cell membrane inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postoperative infections

Most Recent Events

  • 11 Mar 2017 Discontinued - Phase-I/II for Postoperative infections (Adjunctive treatment, Prevention) in USA (Intra-abdominal)
  • 05 Dec 2016 Oculus innovative Sciences is now called Sonoma Pharmaceuticals
  • 06 Aug 2015 Pulmatrix terminates a phase I/II trial in Post-operative infections in USA (NCT02280395)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top